Analysis of Hydroxychloroquine Adverse Events Reported in the WHO Pharmacovigilance Database

被引:0
|
作者
Ahmed, Nehad J. [1 ]
Alshehri, Ahmed M. [1 ]
Almalki, Ziyad S. [1 ]
Alahmari, Abdullah K. [1 ]
机构
[1] Prince Sattam Bin Abdulaziz Univ, Coll Pharm, Dept Clin Pharm, Alkharj, Saudi Arabia
来源
LATIN AMERICAN JOURNAL OF PHARMACY | 2023年 / 42卷 / 01期
关键词
adverse events; hydroxychloroquine; parmacovigilance; vigibase; CHLOROQUINE;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The drug hydroxychloroquine has been in use for a very long time. It is most frequently used to prevent and cure malaria. Hydroxychloroquine has been linked to a number of side effects, with stomach pain being the most frequent. This study used the WHO pharmacovigilance database (VigiBase) for analysis of adverse events related to hydroxychloroquine use. Till 29 June 2022, 34649 reports about the adverse events of hydroxychloroquine were submitted to the WHO pharmacovigilance database (VigiBase). The most reported side effects were general disorders and administration site conditions (37.01%), skin and subcutaneous tissue disorders (21.37%), gastrointestinal disorders (18.53%), injury, poisoning, and procedural complications (16.15%), musculoskeletal and connective tissue disorders (12.71%), investigations (12.00%), nervous system disorders (10.84%), infections and infestations (8.49%), and eye disorders (8.24%). Even though reports of adverse events cannot pinpoint the cause, additional research into some cases might be necessary. Our findings demonstrate the importance of pharmacovigilance and the necessity to inform medical professionals about the safety of hydroxychloroquine.
引用
收藏
页码:25 / 30
页数:6
相关论文
共 50 条
  • [1] Safety of Biologic Therapies for Severe Asthma: An Analysis of Adverse Reactions Reported in the WHO Pharmacovigilance Database
    Cutroneo, P. M.
    Arzenton, E.
    Furci, F.
    Bulzomi, M.
    Caminati, M.
    Senna, G.
    Moretti, U.
    Trifiro, G.
    DRUG SAFETY, 2022, 45 (10) : 1160 - 1161
  • [2] Assessment of Reported Adverse Events After Interchanging Between TNF-α Inhibitor Biosimilars in the WHO Pharmacovigilance Database
    Orhon Pauline
    Marion Robert
    Claire Bernardeau
    Alex Hlavaty
    Michele Fusaroli
    Matthieu Roustit
    Jean-Luc Cracowski
    Charles Khouri
    BioDrugs, 2023, 37 : 699 - 707
  • [3] Assessment of Reported Adverse Events After Interchanging Between TNF-α Inhibitor Biosimilars in the WHO Pharmacovigilance Database
    Pauline, Orhon
    Robert, Marion
    Bernardeau, Claire
    Hlavaty, Alex
    Fusaroli, Michele
    Roustit, Matthieu
    Cracowski, Jean-Luc
    Khouri, Charles
    BIODRUGS, 2023, 37 (05) : 699 - 707
  • [4] Assessment of reported adverse events after substitution between TNF alfa inhibitors biosimilars in the WHO pharmacovigilance database
    Orhon, P.
    Robert, M.
    Bernardeau, C.
    Fusaroli, M.
    Roustit, M.
    Cracowski, J. L.
    Khouri, C.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2023, 37 : 160 - 160
  • [5] Evaluation of adverse events related to musculoskeletal system reported for COVID-19 vaccines in VigiBase: A WHO pharmacovigilance database
    Kaur, Rimple Jeet
    Charan, Jaykaran
    BRITISH JOURNAL OF PHARMACOLOGY, 2023, 180 : 1176 - 1177
  • [6] Safety of Biological Therapies for Severe Asthma: An Analysis of Suspected Adverse Reactions Reported in the WHO Pharmacovigilance Database
    Paola Maria Cutroneo
    Elena Arzenton
    Fabiana Furci
    Fabio Scapini
    Maria Bulzomì
    Nicoletta Luxi
    Marco Caminati
    Gianenrico Senna
    Ugo Moretti
    Gianluca Trifirò
    BioDrugs, 2024, 38 : 425 - 448
  • [7] Safety of Biological Therapies for Severe Asthma: An Analysis of Suspected Adverse Reactions Reported in the WHO Pharmacovigilance Database
    Cutroneo, Paola Maria
    Arzenton, Elena
    Furci, Fabiana
    Scapini, Fabio
    Bulzomi, Maria
    Luxi, Nicoletta
    Caminati, Marco
    Senna, Gianenrico
    Moretti, Ugo
    Trifiro, Gianluca
    BIODRUGS, 2024, 38 (03) : 425 - 448
  • [8] Adverse events associated with dupilumab in the WHO pharmacovigilance
    Bettuzzi, Thomas
    Drucker, Aaron
    Staumont-Salle, Delphine
    Bihan, Kevin
    Lebrun-Vignes, Benedicte
    Sbidian, Emilie
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB136 - AB136
  • [9] Comparison of pharmacovigilance algorithms in reported voriconazole adverse events
    Eiden, Celine
    Grand, Anais
    Peyriere, Helene
    Hillaire-Buys, Dominique
    PHARMACY WORLD & SCIENCE, 2009, 31 (01): : 67 - 67
  • [10] DISPROPORTIONALITY ANALYSIS FOR PHARMACOVIGILANCE OF MEDICAL DEVICE RELATED ADVERSE EVENTS REPORTED TO THE FDA
    Duggirala, H. J.
    Herz, N. D.
    Canos, D. A.
    Sullivan, R.
    Schaaf, Richard
    Pinnow, E.
    Marinac-Dabic, D.
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 2011, 173 : S131 - S131